MXCT - NASDAQ

MaxCyte, Inc.

MXCT·NASDAQ

$1.23

-0.22%

HealthcareMedical - Devices

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$131.76M

EPS-0.4200

P/E Ratio-3.70

Earnings Date08/12/2026

mxct

Other Non-Current Liabilities

Last Annual Value

263.00K

3-Year CAGR

-42%

5-Year CAGR

-16%

10-Year CAGR

Adjust for Inflation

MaxCyte, Inc. Competitors Analysis of Other Non-Current Liabilities

MXCT · NASDAQ

Company	Other Non-Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
MaxCyte, Inc. NASDAQ:MXCT	263.00K	-2.4%	-10.2%	-2.7%
Perspective Therapeutics, Inc. AMEX:CATX	28.55M	N/A	114.8%	48.1%
Atlantic International Corp. NASDAQ:ATLN	0.00	N/A	N/A	N/A
Forte Biosciences, Inc. NASDAQ:FBRX	1.04M	N/A	N/A	23.5%
Hyperfine, Inc. NASDAQ:HYPR	1.73M	200.1%	N/A	N/A
Rapid Micro Biosystems, Inc. NASDAQ:RPID	583.00K	30.4%	-22.0%	N/A
Sight Sciences, Inc. NASDAQ:SGHT	31.00K	-72.9%	-48.8%	N/A
TriSalus Life Sciences, Inc. NASDAQ:TLSI	23.42M	-13.1%	110.9%	N/A
Owlet, Inc. NYSE:OWLT	3.47M	-50.5%	-14.9%	N/A
Armata Pharmaceuticals, Inc. AMEX:ARMP	0.00	N/A	N/A	N/A
LENSAR, Inc. NASDAQ:LNSR	54.89M	82.5%	280.3%	N/A

MaxCyte, Inc. Fair Value Envelope

MXCT · NASDAQ

Our analysis suggests that MXCT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.23, this represents a potential HIDDEN relative to our calculated worth for MaxCyte, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.23

Related Guides

Blog Categories

Continue your MXCT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.